Metagenomi Announces Closing of Initial Public Offering

EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) — Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced the clos­ing of its pre­vi­ous­ly announced ini­tial pub­lic offer­ing of 6,250,000 of its com­mon stock at a price to the pub­lic of $15.00 per share. The aggre­gate gross pro­ceeds to Metageno­mi from the offer­ing were approx­i­mate­ly $93.75 mil­lion, before deduct­ing under­writ­ing dis­counts and com­mis­sions and offer­ing expens­es. In addi­tion, Metageno­mi has grant­ed the under­writ­ers a 30-day option to pur­chase up to an addi­tion­al 937,500 of its com­mon stock at the ini­tial pub­lic offer­ing price less under­writ­ing dis­counts and commissions.

The shares began trad­ing on the Nas­daq Glob­al Select Mar­ket on Feb­ru­ary 9, 2024 under the tick­er sym­bol ​“MGX”.

J.P. Mor­gan, Jef­feries, TD Cowen, Wells Far­go Secu­ri­ties and BMO Cap­i­tal Mar­kets act­ed as book-run­ning man­agers for the offer­ing. Chardan act­ed as lead man­ag­er for the offering.

A reg­is­tra­tion state­ment relat­ing to these secu­ri­ties has been filed with the Secu­ri­ties and Exchange Com­mis­sion and was declared effec­tive on Feb­ru­ary 8, 2024. The offer­ing was made only by means of a prospec­tus. A copy of the final prospec­tus, when avail­able, may be obtained from J.P. Mor­gan Secu­ri­ties LLC, c/​o Broad­ridge Finan­cial Solu­tions, 1155 Long Island Avenue, Edge­wood, New York 11717, tele­phone: 1−866−803−9204, or by email­ing at prospectus-​eq_​fi@​jpmchase.​com; Jef­feries LLC, Attn: Equi­ty Syn­di­cate Prospec­tus Depart­ment, 520 Madi­son Avenue, New York, New York 10022, by tele­phone at (877) 821‑7388 or by email at Prospectus_​Department@​Jefferies.​com; Cowen and Com­pa­ny, LLC, 599 Lex­ing­ton Avenue, New York, NY 10022, by tele­phone at (833) 297‑2926, or by e‑mail at Prospectus_​ECM@​cowen.​com; Wells Far­go Secu­ri­ties, LLC, 90 South 7^th Street, 5^th Floor, Min­neapo­lis, MN 55402, at 800−645−3751 (option #5) or email a request to WFScustomerservice@​wellsfargo.​com; BMO Cap­i­tal Mar­kets Corp., Attn: Equi­ty Syn­di­cate Depart­ment, 151 W 42^nd Street, 32^nd Floor, New York, NY 10036, tel: (800) 414‑3627, or by email at: bmoprospectus@​bmo.​com.

This press release shall not con­sti­tute an offer to sell or the solic­i­ta­tion of an offer to buy these secu­ri­ties, nor shall there be any sale of these secu­ri­ties in any state or juris­dic­tion in which such offer, solic­i­ta­tion or sale would be unlaw­ful pri­or to the reg­is­tra­tion or qual­i­fi­ca­tion under the secu­ri­ties laws of any such state or jurisdiction.

About Metageno­mi

Metageno­mi is a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived tool­box. Metageno­mi is har­ness­ing the pow­er of metage­nomics, the study of genet­ic mate­r­i­al recov­ered from the nat­ur­al envi­ron­ment, to unlock four bil­lion years of micro­bial evo­lu­tion to dis­cov­er and devel­op a suite of nov­el edit­ing tools capa­ble of cor­rect­ing any type of genet­ic muta­tion found any­where in the genome. Its com­pre­hen­sive genome edit­ing tool­box includes pro­gram­ma­ble nucle­as­es, base edi­tors, and RNA and DNA-medi­at­ed inte­gra­tion sys­tems (includ­ing prime edit­ing sys­tems and clus­tered reg­u­lar­ly inter­spaced short palin­dromic repeat-asso­ci­at­ed trans­posas­es. Metageno­mi believes its diverse and mod­u­lar tool­box posi­tions the com­pa­ny to access the entire genome and select the opti­mal tool to unlock the full poten­tial of genome edit­ing for patients. For more infor­ma­tion, please vis­it https://​metageno​mi​.co. 

Cau­tion­ary Note Regard­ing For­ward-Look­ing Statements

This press release includes cer­tain dis­clo­sures that con­tain ​“for­ward-look­ing state­ments,” includ­ing, with­out lim­i­ta­tion, state­ments regard­ing Metagenomi’s expec­ta­tions regard­ing its intend­ed use of the net pro­ceeds from the offer­ing, togeth­er with its exist­ing cash and cash equiv­a­lents and avail­able-for-sale mar­ketable secu­ri­ties. For­ward-look­ing state­ments are based on Metagenomi’s cur­rent expec­ta­tions and are sub­ject to inher­ent uncer­tain­ties, risks and assump­tions that are dif­fi­cult to pre­dict. Fac­tors that could cause actu­al results to dif­fer include, but are not lim­it­ed to, risks and uncer­tain­ties relat­ed to the risks inher­ent in bio­phar­ma­ceu­ti­cal prod­uct devel­op­ment. These and oth­er risks and uncer­tain­ties are described more ful­ly in the sec­tion titled ​“Risk Fac­tors” sec­tion of the reg­is­tra­tion state­ment filed with the Secu­ri­ties and Exchange Com­mis­sion. For­ward-look­ing state­ments con­tained in this announce­ment are made as of this date, and Metageno­mi under­takes no duty to update such infor­ma­tion except as required under applic­a­ble law. Read­ers should not rely upon the infor­ma­tion on this page as cur­rent or accu­rate after its pub­li­ca­tion date.

Investor Con­tact:
Simon Harnest CIO, SVP Strat­e­gy
simon@​metagenomi.​co 

Mar­ket­ing Con­tact:
Ash­lye Hodge Com­mu­ni­ca­tions Man­ag­er
ashlye@​metagenomi.​co